Navigation Links
Xoft Recognized With R&D 100 Award
Date:7/24/2008

R&D Magazine Selects Axxent(R) Miniature Brachytherapy X-ray Source as One of the 100 Most Technologically Significant Products of the Past Year

SUNNYVALE, Calif., July 24 /PRNewswire/ -- Xoft, Inc. today announced that the Axxent(R) High Dose Rate (HDR) X-ray Source has been selected to receive an R&D 100 Award from R&D Magazine as one of the year's most technologically significant products. Established by the editors of R&D Magazine in 1963, the R&D 100 Awards are designed to recognize significant technological achievements and products that leapfrog current technology and that provide simple, elegant solutions to complex or long-standing technical or practical problems.

Over the past 45 years, the R&D 100 Awards have recognized winning products with such household names as the flashcube (1965), the automated teller machine (1973), the fax machine (1975), the liquid crystal display (1980), the Kodak Photo CD (1991), the Nicoderm antismoking patch (1992), Taxol anticancer drug (1993), and HDTV (1998).

"The Axxent miniature X-ray source is a fundamentally new way to deliver therapeutic radiation. Previously, there has been external beam radiation, generally delivered by a linear accelerator, or brachytherapy, a radioactive isotope delivering radiation internal to the body," said Paul Lovoi PhD, CTO and co-founder of Xoft. "The Axxent source can deliver internal or external radiation and, because of the lower energy, can deliver this radiation in any minimally-shielded setting. Until the Xoft miniature X-ray source, there has been no new modality of radiation treatment in over 40 years. The Xoft Axxent X-ray source is the enabling technology for many generations of increasingly more sophisticated, accurate, and accessible radiation treatment systems."

The Axxent(R) HDR X-ray source is a miniature disposable X-ray tube, 2.25 mm in diameter, that can be inserted into the body to deliver a 50 kVp therapeutic dose of radiation for cancer treatment. In comparison, the next smallest medical X-ray source currently in use is more than 10 times larger. The source is part of the Axxent Electronic Brachytherapy System which is FDA cleared for use in the radiation treatment of cancers or other conditions. Specific applicators are cleared for treatment of early stage breast cancer and for endometrial and rectal cancers.

As a platform technology, the Axxent System is designed to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Because of its unique characteristics, radiation from the Axxent HDR X-ray Source can be easily shielded, allowing medical personnel to be present during treatment delivery, minimizing patient anxiety.

"Eliminating the need for the heavily-shielded vaults required by existing radiation therapy technologies, such as radioactive isotopes and linear accelerators, will allow the therapy to move to the patient rather than forcing the patient to come to specialty treatment centers. This will make the best treatment available annually to tens of thousands of cancer patients worldwide that otherwise would not receive it. This is especially important for patients that may not have access to specialized vaults because of the cost of travel and lodging plus the impact of being absent from jobs and families during treatment," said Tom Rusch, PhD, VP of Technical Outreach and Xoft co-founder.

"Known as one of the most prestigious honors in the field of research and development, the R&D 100 Award is a mark of excellence known to industry, government, and academia validating that the product is one of the most innovative ideas of the year," said Michael Klein, president and CEO of Xoft. "We are extremely proud of our R&D team and their efforts to invent and bring to market a paradigm shifting technology in the treatment of cancer. Not only does the Axxent System have the potential to dramatically improve access to an easier and more convenient form of treatment, it also supports the federal government directive to develop viable substitutes for radioactive isotopes which carry environmental and national security concerns."

To learn more about the R&D 100 Awards, visit http://www.RDmag.com

About Xoft, Inc.

Founded in 1998, Xoft develops leading-edge technologies for the practice of radiation oncology through Electronic Brachytherapy, which utilizes proprietary miniaturized X-ray tube technology. The Axxent(R) Electronic Brachytherapy System, Xoft's first treatment system, is currently being used in Accelerated Partial Breast Irradiation (APBI) for the treatment of early-stage breast cancer and in the treatment of endometrial cancer. For more information, visit http://www.xoftinc.com

Axxent is a registered trademark of Xoft, Inc.


'/>"/>
SOURCE Xoft, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ARUP Laboratories ARUP Consult(R) Recognized as a Computerworld Honors Program Laureate
2. Cadient Group Recognized with Five Awards at 14th Annual Communicator Awards
3. Texas Oncology-Baylor Sammons Cancer Center Recognized for Highest Commitment to Clinical Research at ASCO
4. Sigma-Aldrich Recognized by BioInformatics, LLC as Having the Most Useful and Easiest to Use Online and Print Catalogs
5. ARIUS recognized for entrepreneurial excellence
6. NYU chemist Seeman recognized for founding, establishing the field of structural DNA nanotechnology
7. Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction
8. Baxters Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing
9. International Human Rights Day Recognized by Terasem Movement, Inc.s Third Annual Colloquium on the Law of Transbeman Persons
10. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
11. Netsmart Technologies Customer in Pennsylvania Recognized for Achieving Data Benchmarking Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016 ... Police deploy Teleste,s video security solution to ensure the safety ... France during the major tournament Teleste, ... communications systems and services, announced today that its video security ... to back up public safety across the country. ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
Breaking Biology News(10 mins):